Limits...
High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need.

Cimmino G, Ciccarelli G, Morello A, Ciccarelli M, Golino P - Transl Med UniSa (2014)

Bottom Line: Despite aggressive strategies are now available to reduce LDL-cholesterol, the risk of cardiovascular events in patients with coronary artery disease remains substantial.Several preclinical and clinical studies have shown that drug therapy ultimately leads to a regression of the angiographic lesions but also results in a reduction in cardiovascular events.As a result, HDL-based therapeutic interventions that maintain or enhance HDL functionality, such as improving its main property, the reverse cholesterol transport, require closer investigation.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiothoracic and Respiratory Sciences, Second University of Naples, Italy;

ABSTRACT
Despite aggressive strategies are now available to reduce LDL-cholesterol, the risk of cardiovascular events in patients with coronary artery disease remains substantial. Several preclinical and clinical studies have shown that drug therapy ultimately leads to a regression of the angiographic lesions but also results in a reduction in cardiovascular events. The dramatic failure of clinical trials evaluating the cholesterol ester transfer protein (CEPT) inhibitors, torcetrapib and dalcetrapib, has led to considerable doubt about the value of the current strategy to raise high-density lipoprotein cholesterol (HDL-C) as a treatment for cardiovascular disease. These clinical results, as well as animal studies, have revealed the complexity of HDL metabolism, assessing a more important role of functional quality compared to circulating quantity of HDL. As a result, HDL-based therapeutic interventions that maintain or enhance HDL functionality, such as improving its main property, the reverse cholesterol transport, require closer investigation. In this review, we will discuss HDL metabolism and function, clinical-trial data available for HDL-raising agents, and potential strategies for future HDL-based therapies.

No MeSH data available.


Related in: MedlinePlus

Therapeutic Interventions to increase RCT: This is a schematic view of the possible strategies to increase Apo AI functions, via Apo AI mimetic peptides, ApoA-I Milano infusions, ApoA-I viral transfection, recombinant HDL infusion. These interventions may result in an increased RCT, thus removing cholesterol from the body and reducing atherosclerosis
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4592041&req=5

f3-tm-12-29: Therapeutic Interventions to increase RCT: This is a schematic view of the possible strategies to increase Apo AI functions, via Apo AI mimetic peptides, ApoA-I Milano infusions, ApoA-I viral transfection, recombinant HDL infusion. These interventions may result in an increased RCT, thus removing cholesterol from the body and reducing atherosclerosis


High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need.

Cimmino G, Ciccarelli G, Morello A, Ciccarelli M, Golino P - Transl Med UniSa (2014)

Therapeutic Interventions to increase RCT: This is a schematic view of the possible strategies to increase Apo AI functions, via Apo AI mimetic peptides, ApoA-I Milano infusions, ApoA-I viral transfection, recombinant HDL infusion. These interventions may result in an increased RCT, thus removing cholesterol from the body and reducing atherosclerosis
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4592041&req=5

f3-tm-12-29: Therapeutic Interventions to increase RCT: This is a schematic view of the possible strategies to increase Apo AI functions, via Apo AI mimetic peptides, ApoA-I Milano infusions, ApoA-I viral transfection, recombinant HDL infusion. These interventions may result in an increased RCT, thus removing cholesterol from the body and reducing atherosclerosis
Bottom Line: Despite aggressive strategies are now available to reduce LDL-cholesterol, the risk of cardiovascular events in patients with coronary artery disease remains substantial.Several preclinical and clinical studies have shown that drug therapy ultimately leads to a regression of the angiographic lesions but also results in a reduction in cardiovascular events.As a result, HDL-based therapeutic interventions that maintain or enhance HDL functionality, such as improving its main property, the reverse cholesterol transport, require closer investigation.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiothoracic and Respiratory Sciences, Second University of Naples, Italy;

ABSTRACT
Despite aggressive strategies are now available to reduce LDL-cholesterol, the risk of cardiovascular events in patients with coronary artery disease remains substantial. Several preclinical and clinical studies have shown that drug therapy ultimately leads to a regression of the angiographic lesions but also results in a reduction in cardiovascular events. The dramatic failure of clinical trials evaluating the cholesterol ester transfer protein (CEPT) inhibitors, torcetrapib and dalcetrapib, has led to considerable doubt about the value of the current strategy to raise high-density lipoprotein cholesterol (HDL-C) as a treatment for cardiovascular disease. These clinical results, as well as animal studies, have revealed the complexity of HDL metabolism, assessing a more important role of functional quality compared to circulating quantity of HDL. As a result, HDL-based therapeutic interventions that maintain or enhance HDL functionality, such as improving its main property, the reverse cholesterol transport, require closer investigation. In this review, we will discuss HDL metabolism and function, clinical-trial data available for HDL-raising agents, and potential strategies for future HDL-based therapies.

No MeSH data available.


Related in: MedlinePlus